Biocon's JV NeoBiocon launches breast cancer drug in UAE

New Delhi, Oct 9 (UNI) Biotechnology companies NeoBiocon and Abraxis BioScience today announced the launch of Abraxane, used in the treatment of breast cancer, in the UAE.

NeoBiocon is a joint venture between Abu Dhabi's Neopharma and Bangalore-based Biocon Ltd.

Abraxane, a solvent-free chemotherapy treatment option for metastatic breast cancer, is currently available in the UAE as a single-use 100 mg vial.

In August last year, Abraxis established a licencing agreement with Biocon for the commercialisation of Abraxane in India.

Under the terms of the agreement, Biocon has the right to market the drug in India, Pakistan, Bangladesh, Sri Lanka, the United Arab Emirates, Saudi Arabia, Kuwait and certain other South Asian and Persian Gulf countries.

UNI SG RL PM1712